Subtype
Female Reproductive System Neoplasm
CI-CAN-00000885Explore in graph →
Non-malignant1,630 active trials11 approved drugs139 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000885Explore in graph →
Clinical trials
7,171 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06730581 | Utidelone Capsule Monotherapy for Patients with Advanced Solid Tumors | not yet recruiting | Phase 2 | 100 | Beijing Biostar Pharmaceuticals Co., Ltd.INDUSTRY | 0 | Dec 12, 2024 | clinicaltrials |
| NCT05349227 | Comprehensive Outcomes for After Cancer Health(COACH) | recruiting | N/A | 625 | Pack HealthINDUSTRY | 1 | Dec 11, 2024 | clinicaltrials |
| NCT06726291 | Akynzeo as Antiemetic Treatment in Patients With Endometrial Cancer(NOEME) | recruiting | Phase 4 | 84 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT06724263 | A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors | not yet recruiting | Phase 2 | 120 | Tasly Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT05655260 | PErsonalized TReatment for Endometrial Carcinoma(PETREC) | recruiting | N/A | 300 | University of HelsinkiOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT01566240 | Induction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally Advanced Cervical Cancer(INTERLACE) | active not recruiting | Phase 3 | 500 | University College, LondonOTHER | 5 | Dec 5, 2024 | clinicaltrials |
| NCT02321228 | Early Salpingectomy (Tubectomy) With Delayed Oophorectomy in BRCA1/2 Gene Mutation Carriers(TUBA) | active not recruiting | N/A | 510 | University Medical Center NijmegenOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT01276574 | Epithelial Ovarian Cancer- Staging and Response to Chemotherapy Evaluated by PET/CT(Mupet) | active not recruiting | — | 150 | Turku University HospitalOTHER_GOV | 1 | Dec 4, 2024 | clinicaltrials |
| NCT06278857 | SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr)(SATELLITE) | recruiting | Phase 2 | 10 | Queensland Centre for Gynaecological CancerOTHER_GOV | 1 | Dec 3, 2024 | clinicaltrials |
| NCT04713514 | OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC(TEDOVA) | active not recruiting | Phase 2 | 180 | ARCAGY/ GINECO GROUPOTHER | 3 | Dec 2, 2024 | clinicaltrials |
| NCT05652283 | Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer | active not recruiting | Phase 2 | 37 | Bai-Rong XiaOTHER | 1 | Nov 27, 2024 | clinicaltrials |
| NCT06437353 | Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer | recruiting | Phase 2 | 74 | Anhui Provincial Cancer HospitalOTHER | 1 | Nov 27, 2024 | clinicaltrials |
| NCT06603506 | Collection of Endometrial Cancer-derived Organoids to Evaluate the Efficacy of PARP Inhibitors: PENDOR Pilot Study(PENDOR) | recruiting | — | 16 | Centre Francois BaclesseOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT06705322 | Cnidium Monnieri Detoxification Formula for Persistent High-risk Human Papillomavirus Infection of Cervix. | not yet recruiting | Phase 2 | 79 | Fudan UniversityOTHER | 0 | Nov 26, 2024 | clinicaltrials |
| NCT05824975 | A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) | recruiting | Phase 1 / Phase 2 | 358 | GI Innovation, Inc.INDUSTRY | 2 | Nov 25, 2024 | clinicaltrials |
| NCT05927818 | Sentinel Lymph Node Biopsy in Early-Stage Ovarian Cancer | recruiting | N/A | 100 | Istanbul UniversityOTHER | 1 | Nov 25, 2024 | clinicaltrials |
| NCT06703112 | Establishment and Clinical Application of AI-based Multimodal Diagnosis System for Ovarian Tumors | not yet recruiting | N/A | 584 | Beijing Shijitan Hospital, Capital Medical UniversityOTHER | 0 | Nov 25, 2024 | clinicaltrials |
| NCT06692166 | A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer | recruiting | Phase 3 | 420 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Nov 22, 2024 | clinicaltrials |
| NCT02754115 | An Audit of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy | recruiting | — | 400 | Tata Memorial CentreOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT06673511 | The Application of Sentinel Lymph Node Mapping Technique in the Surgery of Early Epithelial Ovarian Cancer | not yet recruiting | N/A | 246 | Anhui Provincial HospitalOTHER_GOV | 0 | Nov 21, 2024 | clinicaltrials |
| NCT06553742 | High Definition Profiling of Ovarian Cancer Ascites | not yet recruiting | — | 50 | European Institute of OncologyOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT06697054 | Sentinel Lymph Node (SLN) Mapping with Charcoal Carbon Dye in Early Stage Cervical Cancer(SLN) | active not recruiting | N/A | 60 | Istanbul UniversityOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT02124421 | HOT: HIPEC in Ovarian Cancer as Initial Treatment(CRS/HIPEC) | active not recruiting | Phase 2 | 32 | Mercy Medical CenterOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT02387203 | Antibiotic Treatment and Long-term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin | active not recruiting | Phase 2 | 80 | Mercy Medical CenterOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT06694116 | Charcoal Carbon Black Dye Use in Sentinel Lymph Node Mapping in Early Stage Vulvar Cancer(IFLND) | active not recruiting | N/A | 40 | Istanbul UniversityOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT05358639 | Combination of Olaparib and Navitoclax in Women with HGSC and TNBC | active not recruiting | Phase 1 | 36 | Sunnybrook Health Sciences CentreOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT05199272 | A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies | active not recruiting | Phase 1 / Phase 2 | 141 | 23andMe, Inc.INDUSTRY | 2 | Nov 15, 2024 | clinicaltrials |
| NCT05694208 | The Effect of Mobile-Based Education Given to Patients Undergoing Gynecological Oncology Surgery on Quality of Life | recruiting | N/A | 84 | Istanbul University - CerrahpasaOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT03948789 | Phase III Study of MR-Guided Focused Ultrasound Surgery for the Treatment of Uterine Fibroids Compared to Myomectomy | active not recruiting | Phase 3 | 127 | Krankenhaus NordwestOTHER | 1 | Nov 13, 2024 | clinicaltrials |
| NCT06686043 | HPV Vaccine, Imiquimod, and Metformin Combination Trial(HPV-VIM) | recruiting | Phase 2 | 85 | Baylor College of MedicineOTHER | 1 | Nov 13, 2024 | clinicaltrials |
| NCT02653118 | Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021) | active not recruiting | — | 4,453 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 12, 2024 | clinicaltrials |
| NCT06681259 | Clinical Specialty Queue For Gestational Trophoblastic Neoplasia | recruiting | — | 1,000 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT03907527 | Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer | active not recruiting | Phase 1 | 71 | Precigen, IncINDUSTRY | 1 | Nov 8, 2024 | clinicaltrials |
| NCT06680791 | Molecular Classification in Relation to Prevention of Endometrial Cancer Recurrence and Lifestyle Factors(MPEC) | recruiting | — | 280 | Lukas VanekOTHER_GOV | 1 | Nov 8, 2024 | clinicaltrials |
| NCT06681636 | Effector and Memory Immune Responses to HPV Vaccination in Vietnamese Women Post Virus Exposure(HPV9vxFSW) | not yet recruiting | Phase 2 | 300 | National Institute of Hygiene and Epidemiology, VietnamOTHER | 2 | Nov 8, 2024 | clinicaltrials |
| NCT06652529 | Phase 1 Dose Escalation and Expansion to Evaluate AROG4-01 in Patients With Advanced Solid Tumors(AROG4-01-01) | not yet recruiting | Phase 1 | 35 | Aromics TherapeuticsINDUSTRY | 0 | Nov 7, 2024 | clinicaltrials |
| NCT06289062 | Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer | recruiting | Phase 2 | 40 | Tongji HospitalOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT06672341 | Clinical Studies of Endometrial Cytology and Cervical Methylation Assays in Endometrial Cancer Screening and Fertility-Preservation Evaluation | not yet recruiting | — | 200 | Yulan RenOTHER | 0 | Nov 5, 2024 | clinicaltrials |
| NCT06672497 | Near Infrared Spectroscopy (NIRS) as a Method for Measuring Oxidative Capacity of Skeletal Muscle Mitochondria in Breast Cancer and All Gynecological Cancer Patients | recruiting | — | 30 | University of South CarolinaOTHER | 1 | Nov 4, 2024 | clinicaltrials |
| NCT06672653 | Tolerance and Effectiveness of C14 on HPV Infection(PREPAP) | not yet recruiting | Phase 1 / Phase 2 | 66 | MGB PharmaINDUSTRY | 1 | Nov 4, 2024 | clinicaltrials |
| NCT04723875 | Postoperative Adjuvant Chemotherapy in Early-stage Cervical Cancer That Not Meet Criteria of Adjuvant Therapeutic According to NCCN Guideline | active not recruiting | Phase 3 | 306 | Huazhong University of Science and TechnologyOTHER | 1 | Nov 1, 2024 | clinicaltrials |
| NCT06583395 | Quest to Analyze One Thousand Humans Meditating(QUANTUM) | enrolling by invitation | — | 3,000 | Tobias Moeller-BertramINDUSTRY | 1 | Nov 1, 2024 | clinicaltrials |
| NCT06288373 | Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC | recruiting | Phase 2 / Phase 3 | 440 | Tongji HospitalOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT06665841 | Correlation Between Selenium Levels in Human Tissues and HPV-related Cervical Lesions and Outcomes(SeHPV) | not yet recruiting | — | 200 | Second Affiliated Hospital of Wenzhou Medical UniversityOTHER | 0 | Oct 30, 2024 | clinicaltrials |
| NCT05403554 | A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers | recruiting | Phase 1 | 70 | Light Chain Bioscience - Novimmune SAINDUSTRY | 2 | Oct 29, 2024 | clinicaltrials |
| NCT06416748 | Minimally Invasive Simple Hysterectomy in Low Risk Cervical Cancer(LASH) | recruiting | N/A | 974 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT04511871 | A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors | active not recruiting | Phase 1 | 12 | Shanghai PerHum Therapeutics Co., Ltd.INDUSTRY | 1 | Oct 28, 2024 | clinicaltrials |
| NCT06416150 | Reducing Urban Cervical Cancer Disparities | recruiting | N/A | 546 | Fox Chase Cancer CenterOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT06656949 | Sentinel Lymph Node Mapping With Different Injection Sites of ICG in Endometrium Cancer(SLN-EC-01) | recruiting | N/A | 42 | Qilu Hospital of Shandong UniversityOTHER | 1 | Oct 24, 2024 | clinicaltrials |
| NCT06497270 | A 3D Bioprinted Hormone-producing Model for BRCA Mutated Patients After Risk Reducing Surgery: the DISC-OVARY Trial(DISC-OVARY) | active not recruiting | N/A | 3 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Oct 23, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Dec 12, 2024source: clinicaltrials